Drug intelligence / Profile preview

HY1004

Development stage: Unknown
Lead developer: Wuhan Healthgen Biotechnology
Modality: Recombinant Proteins and Enzymes

Overview

HY1004 is a recombinant protein drug candidate developed by Wuhan Healthgen Biotechnology Corp. It is being investigated for the treatment of cardiovascular diseases, specifically acute myocardial infarction and ST elevation myocardial infarction. The drug has reached Phase 1 clinical trials in China. Detailed information about its precise mechanism of action, molecular target, or protein structure has not been disclosed in public sources as of June 2025[2][3].

Beyond the preview

Go deeper on HY1004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY1004.

Explore the full profile